Please assess the completion status of the following clinical trial:

Trial Title: Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* Newly diagnosed cases with diagnostic criteria for EoE (ie at least 15 eosinophils per high power field (Magnification 10 times 40 = x400) in any field of view in any esophageal biopsy and concurrent symptoms of esophageal dysfunction mainly dysphagia.~* Women of childbearing age may participate provided that the pregnancy is not planned , and that contraceptive use during therapy. The investigator will arrange a free pregnancy test must be performed within 1 week before treatment and be negative.~* Participation requires oral and written informed and signed consent form (see patient information and consent forms).~Exclusion Criteria:~* Local infection of the pharynx or esophagus , such as fungal, bacterial or viral infection~* Active or latent tuberculosis in respiratory tract~* Recent history of major trauma or major surgery~* Recent significant infection or other physical stress~* Signs or suspicion of dehydration~* History of injury, illness or surgery in the adrenals or pituitary~* Pharynx or esophagussurgery or other trauma in the esophagus (incl. foreign body with a sharp object ) where healing has not taken place. (in case of doubt to be assessed by esophago - gastroscopy.~* Planned elective surgery during treatment~* Pregnancy, ongoing or planned~* Women of childbearing potential not using preventives during the study period~* Glaucoma~* Hypersensitivity to any component in the treatments~* Systemic or local steroid treatment last 4 months~* Contraindication to steroid therapy ( immune deficiency or suppression , stomach ulcers, diabetes)~* Medications that affect oesophageal motility (cisapride, erythromycin ) during the treatment period .~* PPIs during or up to 2 weeks before the treatment period~* Other cause of dysphagia (cancer, connective tissue disease , neurological disease )~* Volunteer who can not consent to the study or complete a questionnaire

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone furoat (Type: EXPERIMENTAL): Mometasone furoate monohydrate. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
- Placebo spray (Type: PLACEBO_COMPARATOR): Placebo. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).